Diabetes mellitus: Novel insights, analysis and interpretation of pathophysiology and complications management with imidazole-containing peptidomimetic antioxidants

Recent Patents on Drug Delivery and Formulation

Volumn 7, Issue 3, 2013, Pages 216-256

  Babizhayev, Mark A ^a,b   Lankin, Vadim Z ^c   Savel'Yeva, Ekaterina L ^a   Deyev, Anatoliy I ^a   Yegorov, Yegor E ^d  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Atherosclerosis; Carcinine; D carnosine; Diabetes complications; Excessive nonenzymatic glycosylation; Increased free radical production; Leucyl histidylhidrazide and patented formulations thereof; Nephropathy; Neuropathy; Non hydrolized carnosine; Ophthalmic prodrug N acetylcarnosine; Patented carnosine mimetics resistant to enzymatic hydrolysis with human carnosinases; Retinopathy; Therapeutic management strategies for Type 2 Diabetes; Universal form of antioxidant and transglycating agents

Indexed keywords

2 3 DIAMINOPHENAZINE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANTIDIABETIC AGENT; CARCININE; CARNOSINE; CERULOPLASMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEMOGLOBIN A1C; HISTAMINE H3 RECEPTOR ANTAGONIST; HYDRALAZINE; HYDROPEROXIDE; IMIDAZOLE CONTAINING PEPTIDOMIMETIC ANTIOXIDANT; LEUCYL HISTIDYLHIDRAZIDE; LINOLEIC ACID; LIPID HYDROPEROXIDE; LOSARTAN; N ACETYLCARNOSINE; N PHENYLTHIAZOLIUM BROMIDE; OLMESARTAN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARBON NUCLEAR MAGNETIC RESONANCE; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; ELECTRON SPIN RESONANCE; ELECTROPHORESIS; ENZYME ACTIVITY; EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; CARNOSINE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPERGLYCEMIA; IMIDAZOLES; PATENTS AS TOPIC; PEPTIDOMIMETICS;

EID: 84889071644     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872211307666131117121058     Document Type: Article

References (203)

1. World Health Organisation Department of Noncommunicable Disease Surveillance (1999). "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. ".
2. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: What is new and what works? Clin Diabet 2003; 21(4): 186-7.
3. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288(20): 2579-88. Comment in: JAMA 2003; 289(14): 1779-80; author reply 1780.
4. Romano AH, Conway T. Evolution of carbohydrate metabolic pathways. Res Microbiol 1996; 147: 448-55.
5. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Comm 1996; 228: 539-43.
6. Swamy MS, Tsai C, Abraham A, Abraham EC. Glycation mediated lens crystallin aggregation and crosslinking by various sugars and sugar phosphates in vitro. Exp Eye Res 1993; 56: 177-185.
7. Baynes JW. From life to death-the struggle between chemistry and biology during aging: Maillard reaction as an amplifier of genomic damage. Biogerontology 2000; 1: 235-46.
8. Vlassara H. Advanced glycation in health and disease: Role of the modern environment. Ann N Y Acad Sci 2005; 1043: 452-60.
9. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
10. Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: A general overview. Hormones (Athens) 2005; 4: 28-37.
11. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-6.
12. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245: 243-50.
13. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates N(epsilon)-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-13.
14. Vander Jagt DL, Hassebrook RK, Hunsaker LA, Brown WM, Royer RE, 2001 Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: Roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact 2001; 130-132: 549-62.
15. Thornalley PJ. Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 2005; 1043: 111-7.
16. Vander Jagt DL, Hassebrook RK, Hunsaker LA, Brown WM, Royer RE. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: Roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact 2001; 130-132: 549-62.
17. Peppa M, Raptis SA. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev 2008; 4: 1-9.
18. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62(4): 427-33.
19. Stadtman ER. Protein oxidation and aging. Science 1992; 257(5074): 1220-4.
20. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408(6809): 239-47.
21. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008; 14(10): 962-8.
22. Bhatwadekar AD, Glenn JV, Li G, Curtis TM, Gardiner TA, Stitt AW. Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: Implications for vasodegeneration in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49(3): 1232-41.
23. Cameron NE, Gibson TM, Nangle MR, Cotter MA. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann NY Acad Sci 2005; 1043: 784-92.
24. Cameron NE, Cotter MA. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies. Diabet Med 1993; 10(7): 593-605.
25. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 1998; 54: 438-47.
26. Gugliucci A, Bendayan M. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin induced rats an ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 1995; 43: 591-600.
27. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci 1994; 91: 9436-40.
28. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999; 341(15): 1127-33.
29. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 2004; 4: 31-36.
30. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-43.
31. Birrell AM, Heffernan SJ, Kirwan P, McLennan S, Gillin AG, Yue DK. The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes. J Diabetes Complications 2002; 16(4): 301-9.
32. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocindiabetic rats. Diabetologia 2003; 46(8): 1140-52.
33. Peppa M, Uribarri J, Vlassara H. Advanced glycoxidation: A new risk factor for cardiovascular disease? Cardiovasc Toxicol 2002; 2: 275-87.
34. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90(14): 6434-8.
35. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. J Biol Chem 1983; 258(15): 9406-12.
36. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-32.
37. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143(6): 1649-56.
38. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99(3): 457-68.
39. Zhang J, Ren S, Shen GX. Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis 2000; 150(2): 299-308.
40. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25(6): 1055-9.
41. Winer N, Sowers JR. Vascular compliance in diabetes. Curr Diab Rep 2003; 3(3): 230-4.
42. Kahn HA, Moorhead HB, 1973 Statistics on blindness in the model reporting area, 1969-1970 U. S. Department of Health, Education, and Welfare Publication No. (NIH) 73-427, U. S. Government Printing Office, Washington.
43. Stitt AW. Advanced glycation: An important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85(6): 746-53.
44. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150(2): 523-31.
45. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277(23): 20309-15.
46. Mamputu JC, Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diab Comp 2002; 16: 284-93.
47. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47(6): 945-52.
48. Koga K, Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M, et al. Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res 2002; 22(1): 13-7.
49. Sulochana KN, Ramprasad S, Coral K, Lakshmi S, Punitham R, Narayanasamy A, Ramakrishnan S. Glycation and glycoxidation studies in vitro on isolated human vitreous collagen. Med Sci Monit 2003; 9(6): BR220-4.
50. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun. 2002; 296(4): 877-82.
51. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27(2): 97-108.
52. Reber F, Geffarth R, Kasper M, Reichenbach A, Schleicher ED, Siegner A, Funk RH. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced glycation end products and ways of protection. Graefes Arch Clin Exp Ophthalmol. 2003; 241(3): 213-25.
53. Hammes HP, Wellensiek B, Klöting I, Sickel E, Bretzel RG, Brownlee M. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998; 41(2): 165-70.
54. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991 Dec 15; 88(24): 11555-8. Erratum in: Proc Natl Acad Sci USA 1992 Oct 1; 89(19): 9364.
55. Swamy-Mruthinti S, Shaw SM, Zhao HR, Green K, Abraham EC. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr Eye Res 1999; 18(6): 423-9.
56. Franke S, Dawczynski J, Strobel J, Niwa T, Stahl P, Stein G. Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg 2003; 29(5): 998-1004.
57. Matsumoto K, Ikeda K, Horiuchi S, Zhao H, Abraham EC. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. Biochem Biophys Res Commun 1997; 241(2): 352-4.
58. Zhao HR, Nagaraj RH, Abraham EC. The role of alpha-and epsilon-amino groups in the glycation-mediated cross-linking of gammaB-crystallin. Study of three site-directed mutants. J Biol Chem. 1997; 272(22): 14465-9.
59. Zhao W, Devamanoharan PS, Varma SD. Fructose-mediated damage to lens alpha-crystallin: Prevention by pyruvate. Biochim Biophys Acta 2000; 1500(2): 161-8.
60. Zhao W, Devamanoharan PS, Varma SD. Fructose induced deactivation of antioxidant enzymes: Preventive effect of pyruvate. Free Radic Res 2000; 33(1): 23-30.
61. Stevens A. The contribution of glycation to cataract formation in diabetes. J Am Optom Assoc 1998; 69(8): 519-30.
62. Sebag J, Buckingham B, Charles MA, Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992; 110(10): 1472-6.
63. Stitt AW, Moore JE, Sharkey JA, Murphy G, Simpson DA, Bucala R, Vlassara H, Archer DB. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Vis Sci 1998; 39(13): 2517-23.
64. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993; 43(4): 817-24. Erratum in: Neurology 1993 Nov; 43(11): 2345.
65. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: A review. J Neuropathol Exp Neurol 1996; 55(12): 1181-93. Comment in: J Neuropathol Exp Neurol 1997; 56(4): 458.
66. Boel E, Selmer J, Flodgaard HJ, Jensen T. Diabetic late complications: Will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? J Diabetes Complications 1995; 9(2): 104-29.
67. Poduslo JF, Curran GL. Increased permeability across the bloodnerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci USA 1992; 89(6): 2218-22.
68. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997; 40: 1380-7.
69. Graham AR, Johnson PC. Direct immunofluorescence findings in peripheral nerve from patients with diabetic neuropathy. Ann Neurol 1985; 17: 450-4.
70. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA 1981; 78(8): 5190-2.
71. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, Li Z, Croitoru A, Thung S, Vlassara H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003; 52(11): 2805-13.
72. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48(4): 870-80.
73. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99(3): 457-68.
74. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44(7): 824-9.
75. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159(2): 513-25. Comment in: Am J Pathol 2001; 159(2): 399-403.
76. Portero-Otín M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes 2002; 51(5): 1535-42.
77. Kochakian M, Manjula BN, Egan JJ. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZinduced diabetic rats. Diabetes 1996; 45: 1694-700.
78. Teixeira AS, Caliari MV, Rocha OA, Machado RD, Andrade SP. Aminoguanidine prevents impaired healing and deficient angiogenesis in diabetic rats. Inflammation 1999; 23: 569-81.
79. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001; 10(11): 1977-87.
80. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44(1): 108-14.
81. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51(11): 3283-9.
82. Oturai PS, Christensen M, Rolin B, Pedersen KE, Mortensen SB, Boel E. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. Metabolism 2000; 49(8): 996-1000.
83. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272(9): 5430-7.
84. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, Geyer J, Köpcke W, Sauerland C, Bretzel RG, Federlin KF. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001; 109(6): 330-6.
85. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000; 275(28): 21177-84.
86. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46(5): 895-9.
87. Schwedler SB, Verbeke P, Bakala H, Weiss MF, Vilar J, Depreux P, et al. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. Diabetes Obes Metab 2001; 3(4): 230-9.
88. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17(12): 1762-4. Epub 2003 Jul 18.
89. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001; 98(3): 1171-5.
90. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A. Advanced glycation endproduct levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrol Metab 1999; 25: 380-83.
91. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13(10): 2478-87.
92. Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy] [Article in Danish] Ugeskr Laeger 2001; 163(40): 5514-9.
93. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60(1): 228-34.
94. Severin S. E. Problems concerned with the biological activity of naturally occurring imidazole compounds. Proceedings of Plen. Sess. Seventh International Biochemical Congress 1964, NY, pp. 45-61.
95. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: Distribution, properties and biological significance. Adv Enzyme Regul 1990; 30: 175-194.
96. Lenney JF. Specificity and distribution of mammalian carnosinase. Biochim Biophys Acta 1976; 429(1): 214-9.
97. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta 1991; 196(2-3): 193-205.
98. Lenney JF. Separation and characterization of two carnosinesplitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase). Biol Chem Hoppe Seyler 1990; 371(5): 433-40.
99. Kunze N, Kleinkauf H, Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. Eur J Biochem 1986; 160(3): 605-13.
100. Aldini G, Facino RM, Beretta G, Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives. Biofactors 2005; 24(1-4): 77-87.
101. Aldini G, Orioli M, Carini M, Maffei Facino R. Profiling histidinecontaining dipeptides in rat tissues by liquid chromatography/electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004; 39(12): 1417-28.
102. Orioli M, Aldini G, Beretta G, Facino RM, Carini M. LC-ESIMS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 827(1): 109-18.
103. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ. 2005; 2005(18): pe12.
104. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007; 581 (5): 1067-70.
105. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22: 979-94.
106. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, et al. Efficacy of Nacetylcarnosine in the treatment of cataracts. Drugs Res Develop 2002; 3(2): 87-103.
107. Babizhayev MA, Deyev AI, Yermakova VN, Remenschikov VV, Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Therap 2006; 1: 91-116.
108. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours, J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs Res Develop 2004; 5(3): 125-39.
109. Babizhayev, M. A. Method for topical treatment of eye disease and composition and device for said treatment. WO2004028536A1 (2004).
110. Babizhayev MA. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol 2006; 1(3): 201-33.
111. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res 2004; 7: 186-98.
112. Babizhayev MA, Yermakova VN, Deyev AI, Seguin M-C. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti-Aging Med 2000; 3: 43-62.
113. Arnould JM, Frentz R. Presence, isolation and chemical structure of a substance characteristic of cardiac tissue in Carcinus maenas (L.): Beta-alanylhistamine. Comp Biochem Physiol C 1975; 50(1): 59-66.
114. Brotman DN, Flancbaum L, Fitzpatrick JC, Fisher H. Presence of carcinine (β-alanylhistamine) in mammalian tissues. FASEB J 1989; 3: 1028.
115. Brotman DN, Flancbaum L, Kang YH, Merrill GF, Fisher H. Positive inotropic effects of carcinine in the isolated, perfused guinea pig heart. Crit Care Med 1990; 18: 317-21.
116. Flancbaum L, Brotman DN, Fitzpatrick JC, Van Es T, Kasziba E, Fisher H. Existence of carcinine, a histamine-related compound, in mammalian tissues. Life Sci 1990; 47: 1587-93.
117. Ali SM, Tedford CE, Gregory R, Handley MK, Yates SL, Hirth WW, Phillips JG. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J Med Chem 1999; 42: 903-9.
118. Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Handley MK, Yates SL. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289: 1160-8.
119. Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289(2): 1151-9.
120. Tozer MJ, Kalindjian SB. Histamine H3 receptor antagonists. Exp Opin Ther Patents 2000; 10: 1045-55.
121. Chen Z, Sakurai E, Hu W, Jin C, Kiso Y, Kato M, et al. Pharmacological effects of carcinine on histaminergic neurons in the brain. Br J Pharmacol 2004; 143(5): 573-80. Epub 2004 Oct 4.
122. Babizhayev MA. Biological activities of the natural imidazolecontaining peptidomimetics n-acetylcarnosine, carcinine and Lcarnosine in ophthalmic and skin care products. Life Sci 2006 Apr 11; 78(20): 2343-57. Epub 2006 Jan 4.
123. Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem J 1994; 304 (Pt 2): 509-16.
124. Arnould JM, Frentz R. Carcinine (β-alanyl-histamine): Rapid synthesis and action on vertebrate blood pressure. Arch Int Physiol Biochim 1977; 85(2): 339-50.
125. Babizhayev, M. A., Meguro, K. Combined use of carnosinase inhibitor with L-carnosines and composition. WO2004064866 (2004).
126. Babizhayev MA, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J Drug Target 2009; 17(1): 36-63.
127. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 1997; 322 (Pt 1): 317-25.
128. Thornalley PJ. Monosaccharide autoxidation in health and disease. Environ Health Perspect 1985; 64: 297-307.
129. Stewart JJP, Mopac FJ. Seiler Research Laboratory. Air Force Academy, Boulder 1989; 80840.
130. Stewart JJ. MOPAC. Ver. 6, QCPE Bull. 9, 10. Revised as Ver. 6. 01 by T. Hirano, University of Tokyo, for HITAC and UNIX machines (JCPE Newsletter., 1989. 1, 10).
131. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochimica et Biophysica Acta 1989; 1004: 363-71.
132. Babizhayev MA, Bozzo Costa E. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochimica et Biophysica Acta 1994; 1225: 326-37.
133. Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Kondo M. The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinato zinc. Biochim Biophys Acta 1991; 1115(1): 15-22.
134. Iacazio G, Langrand G, Baratti J, Buono G, Triantaphylides CJ. Preparative, enzymatic synthesis of linoleic acid (13S)-hydroperoxide using soybean lipoxygenase-1. Org Chem 1993; 55: 1690.
135. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680.
136. Sammons DW, Adams LD, Nishizawa EE. Ultra sensitive silver based color staining of polypeptides in polyacrylamide gels. Electrophoresis 1981; 2: 135.
137. Guiotto A, Ruzza P, Babizhayev MA, Calderan A. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem 2007; 15(18): 6158-63. Epub 2007 Jun 20.
138. Szwergold B. S. Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophysic Res Commun 2005; 336(1): 36-41.
139. Bando K, Shimotsuji T, Toyoshima H, Hayashi C, Miyai K. Fluorometric assay of human serum carnosinase activity in normal children, adults and patients with myopathy. Ann Clin Biochem 1984; 21 (Pt 6): 510-14.
140. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25(3-4): 275-81. Epub 2003 Jul 29.
141. Bourajjaj M, Stehouwer CD, van Hinsbergh VW, Schalkwijk CG. Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. Biochem Soc Trans 2003; 31(Pt 6): 1400-2.
142. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med 1993; 14(4): 287-371.
143. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alphaacetyllysine, and bovine serum albumin. J Biol Chem 1994; 269(51): 32299-305.
144. Suji G, Sivakami S. DNA damage during glycation of lysine by methylglyoxal: assessment of vitamins in preventing damage. Amino Acids 2007; 33(4): 615-21.
145. Yim HS, Kang SO, Hah YC, Chock PB, Yim MB. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 1995; 270(47): 28228-33.
146. McLaughlin JA, Pethig R, Szent-Györgyi A. Spectroscopic studies of the protein-methylglyoxal adduct. Proc Natl Acad Sci USA 1980; 77(2): 949-51.
147. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: In vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004; 286(3): R431-44.
148. Shumaev KB, Gubkina SA, Kumskova EM, Shepelkova GS, Ruuge EK, Lankin VZ. Superoxide formation as a result of interaction of L-lysine with dicarbonyl compounds and its possible mechanism. Biochemistry (Mosc) 2009; 74(4): 461-6.
149. Bisby RH, Parker AW. Reactions of the alpha-tocopheroxyl radical in micellar solutions studied by nanosecond laser flash photolysis. FEBS Lett 1991; 290(1-2): 205-8.
150. Aldini G, Carini M, Beretta G, Bradamante S, Facino RM. Carnosine is a quencher of 4-hydroxy-nonenal: Through what mechanism of reaction? Biochem Biophysic Res Commun 2002; 298: 699-706.
151. Pegova A, Abe H, Boldyrev A. Hydrolysis of carnosine and related compounds by mammalian carnosinases. Comparat Biochem Physiol Part B 2000; 127: 443-46.
152. Babizhayev MA. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm 2008; 34(10): 1071-89.
153. Kang JH. Protective effects of carnosine and N-acetylcarnosine on salsolinol-mediated Cu, Zn-superoxide dismutase inactivation. Bull Korean Chem Soc 2007; 208(10): 1881-4.
154. Neglia CI, Cohen HJ, Garber AR, Thorpe SR, Baynes JW. Characterization of glycated proteins by 13C NMR spectroscopy. Identification of specific sites of protein modification by glucose. J Biol Chem 1985; 260(9): 5406-10.
155. Mossine VV, Glinsky GV, Feather MS. The preparation and characterization of some Amadori compounds (1-amino-1-deoxy-Dfructose derivatives) derived from a series of aliphatic omegaamino acids. Carbohydr Res 1994; 262(2): 257-70.
156. Babizhayev, M. A., Seguin, M.-C. Coupling product obtained from histamine and an amino acid. US5792784 (1998).
157. Conner JR, Beisswenger PJ, Szwergold BS. Some clues as to the regulation, expression, function, and distribution of fructosamine-3-kinase and fructosamine-3-kinase-related protein. Ann NY Acad Sci 2005; 1043: 824-36.
158. Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003; 278(8): 6521-31. Epub 2002 Dec 6.
159. Unno H, Yamashita T, Ujita S, Okumura N, Otani H, Okumura A, Nagai K, Kusunoki M. Structural basis for substrate recognition and hydrolysis by mouse carnosinase CN2. J Biol Chem 2008; 283(40): 27289-99. Epub 2008 Jun 12.
160. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005; 513(1-2): 145-50. Epub 2005 Apr 2.
161. Babizhayev MA. Current ocular drug delivery challenges for nacetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Rec Pat Drug Deliv Formul 2009; 3(3): 229-65.
162. Amaral ME, Oliveira HC, Carneiro EM, Delghingaro-Augusto V, Vieira EC, Berti JA, et al. Plasma glucose regulation and insulin secretion in hypertriglyceridemic mice. Horm Metab Res 2002; 34: 21-6.
163. Strippoli GF, Di Paolo S, Cincione R, Di Palma AM, Teutonico A, Grandaliano G, et al. Clinical and therapeutic aspects of diabetic nephropathy. J Nephrol 2003; 16: 487-99.
164. Goldberg RB. Cardiovascular disease in patients who have diabetes. Cardiol Clin 2003; 21: 399-413.
165. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-80.
166. Yamada T, Sato A, Nishimori T, Mitsuhashi T, Terao A, Sagai H, et al. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract 2000; 49: 23-31.
167. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature (Lond.) 2001; 414: 813-20.
168. Reynolds TM. Chemistry of nonenzymic browning. I. The reaction between aldoses and amines. Adv Food Res 1963; 12: 1-52.
169. Reynolds TM. Chemistry of nonenzymic browning. II. Adv Food Res 1965; 14: 167-283.
170. Kato H, Hayase F, Shin DB, Oimomi M, Baba S. 3-Deoxyglucosone, an intermediate product of the Maillard reaction. Prog Clin Biol Res 1989; 304: 69-84.
171. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314(7): 403-8.
172. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81(2): 583-7.
173. Monnier VM, Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science 1981; 211(4481): 491-3.
174. Liang JN, Hershorin LL, Chylack LT Jr. Non-enzymatic glycosylation in human diabetic lens crystallins. Diabetologia 1986; 29(4): 225-8.
175. Vlassara H, Brownlee M, Cerami A. Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 1983; 32(7): 670-4.
176. Hicks M, Delbridge L, Yue DK, Reeve TS. Catalysis of lipid peroxidation by glucose and glycosylated collagen. Biochem Biophys Res Commun 1988; 151(2): 649-55.
177. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87(2): 432-8.
178. Simpson JA, Narita S, Gieseg S, Gebicki S, Gebicki JM, Dean RT. Long-lived reactive species on free-radical-damaged proteins. Biochem J 1992; 282 (Pt 3): 621-4.
179. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101(4): 527-37.
180. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173(3): 932-9.
181. Sell DR, Monnier VM. Structure elucidation of a senescence crosslink from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989; 264(36): 21597-602.
182. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85(2): 380-4.
183. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991; 266(18): 11649-53.
184. Sell DR, Nagaraj RH, Grandhee SK, Odetti P, Lapolla A, Fogarty J, et al. Pentosidine: A molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev. 1991; 7(4): 239-51.
185. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266(18): 11654-60.
186. Miyata S, Monnier V. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992; 89(4): 1102-12.
187. Namiki M, Hayashi T, Ohta Y. Novel free radicals formed by the amino-carbonyl reactions of sugars with amino acids, amines, and proteins. Adv Exp Med Biol 1977; 86B: 471-501.
188. Hayashi T, Ohta Y, Namiki M. Electron spin resonance spectral study on the structure of the novel free radical products formed by the reactions of sugars with amino acids or amines. J Agric Food Chem 1977; 25(6): 1282-7.
189. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsiloncarboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261(11): 4889-94.
190. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40(4): 405-12.
191. Dunn JA, Ahmed MU, Murtiashaw MH, Richardson JM, Walla MD, Thorpe SR, et al. Reaction of ascorbate with lysine and protein under autoxidizing conditions: Formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990; 29(49): 10964-70.
192. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: Age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry 1989; 28(24): 9464-8.
193. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91(6): 2463-9.
194. Thornalley P, Wolff S, Crabbe J, Stern A. The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. Biochim Biophys Acta 1984; 797(2): 276-87.
195. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245(1): 243-50.
196. Jiang ZY, Woollard AC, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett 1990; 268(1): 69-71.
197. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988; 256(1): 205-12.
198. Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990; 39(11): 1420-4.
199. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003; 25(3-4): 207-18. Epub 2003 Jul 29.
200. Bonfanti L, Peretto P, De Marchis S, Fasolo A. Carnosine-related dipeptides in the mammalian brain. Prog Neurobiol 1999; 59(4): 333-53.
201. Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: Its properties, functions and potential therapeutic applications. Mol Aspects Med 1992; 13(5): 379-444.
202. Hipkiss AR. Would carnosine or a carnivorous diet help suppress aging and associated pathologies? Ann NY Acad Sci 2006; 1067: 369-74.
203. Hipkiss AR. Carnosine, diabetes and Alzheimer's disease. ExpRev Neurother 2009; 9(5): 583-5. doi: 10. 1586/ern. 09. 32.